Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pct Therapeutics IncfiledCriticalPct Therapeutics Inc
Priority to CU20050190ApriorityCriticalpatent/CU23585B7/en
Publication of CU23585B7publicationCriticalpatent/CU23585B7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms
(AREA)
Abstract
Se describen compuestos de ácido 1,2,4-oxidiazolbenzoico novedosos, método de utilización y composiciones farmacéuticas que comprenden un derivado del ácido 1,2,4-oxidiazolbenzoico. Los métodos incluyen métodos para tratar o evitar una enfermedad mejorada por la modulación de terminación de la traducción prematura o descomposición del ARNm mediado sin sentido, o mejorado uno o más síntomas asociados con la misma.Novel 1,2,4-oxidiazolbenzoic acid compounds, method of use and pharmaceutical compositions comprising a derivative of 1,2,4-oxidiazolbenzoic acid are described. The methods include methods to treat or prevent an improved disease by modulating termination of premature translation or decomposition of the nonsense mediated mRNA, or improved one or more symptoms associated therewith.
CU20050190A2005-10-122005-10-12
1,2,4-BENZOIC OXADIAZOL AND ITS USE FOR THE SUPPRESSION AND TREATMENT OF DISEASES
CU23585B7
(en)
NEW PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ACID 4- (4- (3- (4-CHLORINE-3- TRIFLUOROMETIL-PHENYL) - UREIDO) -3-FLUORO-PHENOXI) -PIRIDIN-2-CARBOXYLIC FOR THE TREATMENT OF HYPERPROLIFERAL DISORDERS.
COMPOUND 5 - OXO - REPLACED PIRROLIDIN, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF GLAUCOMA.
Antibody that recognizes residues 28-35 of beta-amyloid peptide, a pharmaceutical composition that comprises it, useful for treating a disease related to beta-amyloid peptide.
Compounds derived from 3- [4- (oxo-dihydropyridin) benzyl] -1,3-oxazin-one hydrated, 11beta-hsd1 inhibitors; pharmaceutical composition comprising them; and its use in the treatment of diabetes
Compounds derived from spiro-oxindole; sodium channel modulators; pharmaceutical composition comprising said compound; and use in the treatment of pain, depression, cardiovascular, respiratory, psychiatric diseases, among others.
Carbazole derived compounds, hsp90 protein inhibitors; procedure for preparing the compounds; intermediate compounds, pharmaceutical composition comprising one of the compounds; and the use of the compounds in the treatment of cancer.
Compounds derived from 2,4-pyrimidinone condensed with a heterocycle, pde-4 inhibitors; pharmaceutical composition; pharmaceutical combination; compound preparation procedure, useful for treating immune and inflammatory disorders.
Method for treating or preventing cancer, which comprises administering a synergistic pharmaceutical combination of: a) (s) -n- (3,4-difluoro-2- (2-fluoro-4-iodophenylamino) -6-methoxyphenyl) -1 - (2,3-dihydroxypropyl) cyclopropan-1-sulfonamide and b) 3- (6,7-bis (2-methoxyethoxy) quinazolin-4-ylamino) benzonitrile; pharmaceutical composition; and pharmaceutical kit.
Substituted sulfonamide derivative compounds, bradykinin receptor modular; process for its preparation; pharmaceutical composition containing the compounds; and use in the treatment of acute, neuropathic or chronic pain, among others.
Compounds derived from 3- (1 h-pyrrol-2-yl-methyl) -1, 3-dihydro-2h-indol-2-one; procedures for the preparation of said compounds; pharmaceutical composition and pharmaceutical combination comprising them; and its use for the treatment of cancer.